AU2003210598A1 - Treatment of sleep disorders using sleep target modulators - Google Patents
Treatment of sleep disorders using sleep target modulators Download PDFInfo
- Publication number
- AU2003210598A1 AU2003210598A1 AU2003210598A AU2003210598A AU2003210598A1 AU 2003210598 A1 AU2003210598 A1 AU 2003210598A1 AU 2003210598 A AU2003210598 A AU 2003210598A AU 2003210598 A AU2003210598 A AU 2003210598A AU 2003210598 A1 AU2003210598 A1 AU 2003210598A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- group
- therapeutic compound
- therapeutic
- sleep
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34991202P | 2002-01-18 | 2002-01-18 | |
| US60/349,912 | 2002-01-18 | ||
| US35732002P | 2002-02-15 | 2002-02-15 | |
| US60/357,320 | 2002-02-15 | ||
| PCT/US2003/001845 WO2003068148A2 (en) | 2002-01-18 | 2003-01-21 | Treatment of sleep disorders using sleep target modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003210598A2 AU2003210598A2 (en) | 2003-09-04 |
| AU2003210598A1 true AU2003210598A1 (en) | 2003-09-04 |
Family
ID=27737408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003210598A Abandoned AU2003210598A1 (en) | 2002-01-18 | 2003-01-21 | Treatment of sleep disorders using sleep target modulators |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20030232839A1 (https=) |
| EP (1) | EP1471913A2 (https=) |
| JP (1) | JP2005519073A (https=) |
| AU (1) | AU2003210598A1 (https=) |
| CA (1) | CA2473586A1 (https=) |
| WO (1) | WO2003068148A2 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY28538A1 (es) * | 2003-09-26 | 2005-04-29 | Vertex Pharma | Derivados de fenil-piperazina como moduladores de receptores muscarínicos |
| WO2005107700A2 (en) * | 2004-04-26 | 2005-11-17 | Immuneregen Biosciences, Inc. | Anti-aging effects of substance p |
| JP4613031B2 (ja) * | 2004-05-06 | 2011-01-12 | エスエス製薬株式会社 | 催眠剤組成物 |
| DK1940467T3 (da) * | 2005-09-09 | 2017-02-13 | Paladin Labs Inc | Lægemiddelsammensætning med langvarig frigivelse |
| CN101252932B (zh) * | 2005-09-09 | 2012-10-03 | 安吉利尼莱博法姆有限责任公司 | 用于一天给药一次的曲唑酮组合物 |
| CA2641821C (en) | 2006-02-16 | 2017-10-10 | Imthera Medical, Inc. | An rfid-based apparatus, system, and method for therapeutic treatment of a patient |
| US20110077200A1 (en) * | 2006-12-06 | 2011-03-31 | Somaxon Pharmaceuticals, Inc. | Combination therapy using low-dose doxepin for the improvement of sleep |
| CA2697826A1 (en) | 2007-10-09 | 2009-04-16 | Imthera Medical, Inc. | System and method for neural stimulation |
| EP2349139B1 (en) | 2008-10-09 | 2017-05-31 | Imthera Medical, Inc. | Stimulation of a hypoglossal nerve for controlling the position of a patient's tongue |
| ES2370147T5 (es) † | 2009-10-23 | 2019-03-06 | Gruppo Cimbali Spa | Máquina de café con regulación de presión de distribución y procedimiento relacionado con la misma |
| KR20120101650A (ko) | 2009-11-10 | 2012-09-14 | 임테라 메디칼, 인코포레이티드 | 환자 혀의 위치를 제어하기 위한 혀밑 신경 자극용 시스템 |
| US9532952B2 (en) | 2011-01-28 | 2017-01-03 | Physician's Seal, LLC | Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients |
| US8691275B2 (en) | 2011-01-28 | 2014-04-08 | Zx Pharma, Llc | Controlled-release melatonin compositions and related methods |
| AU2012214553B2 (en) | 2011-02-11 | 2015-07-09 | Sociétés des Produits Nestlé S.A. | Multiparticulate L-menthol formulations and related methods |
| US8808736B2 (en) | 2011-02-11 | 2014-08-19 | Zx Pharma, Llc | Enteric coated multiparticulate controlled release peppermint oil composition and related methods |
| US8911780B2 (en) | 2011-02-11 | 2014-12-16 | Zx Pharma, Llc | Multiparticulate L-menthol formulations and related methods |
| US20120315337A1 (en) * | 2011-06-07 | 2012-12-13 | Shah Syed | Multiparticulate 5-htp compositions and related methods |
| WO2013074390A1 (en) * | 2011-11-14 | 2013-05-23 | Merck Sharp & Dohme Corp. | Triazolopyridinone pde10 inhibitors |
| ES2706152T3 (es) | 2013-04-23 | 2019-03-27 | Zx Pharma Llc | Composición entérica de múltiples partículas revestida con subrevestimiento proteico |
| US10420756B2 (en) | 2015-03-26 | 2019-09-24 | Sen-Jam Pharmaceutical Llc. | Methods and compositions to inhibit symptoms associated with veisalgia |
| JP7345495B2 (ja) * | 2018-04-06 | 2023-09-15 | ビーエーエスエフ ソシエタス・ヨーロピア | アミンを合成する方法 |
| EP4615585A1 (en) * | 2022-11-11 | 2025-09-17 | Gilgamesh Pharmaceuticals, Inc. | Methods of using trazodone to reverse the effects of 5-ht2a receptor agonists |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5116852A (en) * | 1990-12-03 | 1992-05-26 | Bristol-Myers Squibb Co. | Treatment of sleep disorders |
-
2003
- 2003-01-21 CA CA002473586A patent/CA2473586A1/en not_active Abandoned
- 2003-01-21 US US10/349,164 patent/US20030232839A1/en not_active Abandoned
- 2003-01-21 WO PCT/US2003/001845 patent/WO2003068148A2/en not_active Ceased
- 2003-01-21 AU AU2003210598A patent/AU2003210598A1/en not_active Abandoned
- 2003-01-21 US US10/501,855 patent/US20060009465A1/en not_active Abandoned
- 2003-01-21 EP EP03739676A patent/EP1471913A2/en not_active Withdrawn
- 2003-01-21 JP JP2003567333A patent/JP2005519073A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003210598A2 (en) | 2003-09-04 |
| CA2473586A1 (en) | 2003-08-21 |
| US20060009465A1 (en) | 2006-01-12 |
| US20030232839A1 (en) | 2003-12-18 |
| EP1471913A2 (en) | 2004-11-03 |
| JP2005519073A (ja) | 2005-06-30 |
| WO2003068148A3 (en) | 2004-04-01 |
| WO2003068148A2 (en) | 2003-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20030232839A1 (en) | Treatment of sleeping disorders using CNS sleep target modulators | |
| US7355042B2 (en) | Treatment of CNS disorders using CNS target modulators | |
| US20040142972A1 (en) | CNS target modulators | |
| CZ179598A3 (cs) | Nové metody a použití | |
| HUT75878A (en) | N-substituted azaheterocyclic carboxylic acids and esters thereof, pharmaceutical compositions containing them, process for their preparation and their use for treatment of neurogenic inflammations | |
| CN1028756C (zh) | 新的吡啶基和嘧啶基衍生物的制备方法 | |
| CN101970427A (zh) | 治疗疼痛症状及其它失调的方法 | |
| US7189757B2 (en) | Treatment of sleep disorders using CNS target modulators | |
| CN115304590A (zh) | 2h-苯并三氮唑衍生物及其制备方法及含有它们的药物组合物 | |
| KR20210065944A (ko) | Dp 길항제 | |
| JP7502429B2 (ja) | 神経因性疼痛の治療におけるフェニルキノリノン系誘導体およびフラボノイド系誘導体の使用 | |
| JPH06511231A (ja) | ２−（ピロリジニル−１−メチル）−ピペリジン誘導体およびκ受容体アゴニストとしてのその使用 | |
| CN87105791A (zh) | 喹唑啉二酮和吡啶并嘧啶二酮及其制备方法 | |
| WO2007092334A1 (en) | Method of treating sleep disorders | |
| WO2007092333A1 (en) | Use of olopatadine for treating sleep disorders | |
| US5180726A (en) | 4-[4- or 6-(trifluoromethyl-2-pyridinyl)]-1-piperazinylalkyl substituted lactams | |
| JPWO2005113501A1 (ja) | 神経因性疼痛制御剤組成物 | |
| KR20090057055A (ko) | 옥세핀 유도체 | |
| CA1132558A (en) | Quinazoline antihypertensives | |
| KR20070018077A (ko) | 신경인성 동통제어 조성물 | |
| AU2006201053A1 (en) | Materials and methods for the treatment of gastroesophageal reflux disease | |
| JP2000507569A (ja) | 抗精神病薬ならびに鎮痛薬を製造するための、１，１―ジアルキル―１，２，３，４―テトラヒドロイソキノリンの使用 | |
| JPH04208283A (ja) | 新規な複素環式化合物およびそれを含有する医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 AUG 2004 |
|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |